7 Participants Needed

Imiquimod + Pembrolizumab for Skin Cancer

No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial studies the effects of combining imiquimod and pembrolizumab to treat advanced melanoma. Imiquimod boosts the immune system, and pembrolizumab helps the immune system attack cancer cells. Pembrolizumab is a standard treatment for advanced melanoma, and imiquimod has shown promise in treating melanoma metastases. The goal is to see if this combination works better than current treatments.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, it mentions that you should not have received certain cancer treatments recently, and you should not have active infections or uncontrolled illnesses. It's best to discuss your current medications with the trial team to be sure.

Is the combination of Imiquimod and Pembrolizumab safe for treating skin cancer?

Pembrolizumab, also known as KEYTRUDA, has been shown to be generally safe in humans, with common side effects including fatigue, rash, itching, and diarrhea. Less common side effects can include inflammation of the lungs (pneumonitis), thyroid issues, and liver inflammation (hepatitis).12345

How is the drug combination of Imiquimod and Pembrolizumab unique for treating skin cancer?

This treatment is unique because it combines Imiquimod, a topical cream that boosts the immune response to fight skin cancer, with Pembrolizumab, an injectable drug that helps the immune system attack cancer cells by blocking a pathway that tumors use to hide from immune cells. This combination leverages both local and systemic immune activation, offering a novel approach compared to traditional treatments like surgery or single-drug therapies.16789

What data supports the effectiveness of the drug Pembrolizumab for skin cancer?

Pembrolizumab has shown strong antitumor activity in skin cancer, specifically in recurrent/metastatic cutaneous squamous cell carcinoma, with meaningful and lasting effects. It has also been effective in treating melanoma, another type of skin cancer, with high response rates and low toxicity.16101112

Who Is on the Research Team?

RC

Ruqin Chen, MD, MB

Principal Investigator

Mayo Clinic

Are You a Good Fit for This Trial?

This trial is for patients with stage IIIB-IV melanoma who haven't had pembrolizumab or similar therapies for metastatic disease. They must have a treatable skin lesion, confirmed diagnosis not suitable for surgery, good performance status and lab values, no severe diseases that could interfere with the trial, no active infections or certain heart conditions, and be willing to use contraception.

Inclusion Criteria

Women who can have children must have a negative pregnancy test.
Willing to return to enrolling institution for follow-up
I have not been treated with pembrolizumab or similar drugs for my metastatic disease.
See 7 more

Exclusion Criteria

I do not have any severe illnesses or social situations that would stop me from following the study's requirements.
I haven't used any experimental treatments or devices for my cancer in the last 4 weeks.
Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
See 19 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive pembrolizumab IV on day 1 and apply imiquimod cutaneously on days 1-5, with cycles repeating every 21 days for up to 2 years

Up to 2 years
Biopsy at baseline, 6 weeks, and 12 weeks; imaging throughout

Follow-up

Participants are monitored for safety and effectiveness after treatment completion

Up to 3 years
Every 12 weeks for 1 year, then every 6 months

What Are the Treatments Tested in This Trial?

Interventions

  • Imiquimod
  • Pembrolizumab
Trial Overview The study tests how well imiquimod (which stimulates the immune system) combined with pembrolizumab (an antibody that may stop tumor growth) treats advanced melanoma. It's a pilot trial to see if this combination works better than current treatments.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: Treatment (pembrolizumab, imiquimod)Experimental Treatment6 Interventions
Patients receive pembrolizumab IV on day 1 and apply imiquimod cutaneously on days 1-5 (Monday - Friday). Cycles repeat every 21 days for up to 2 years (approximately 35 courses) in the absence of disease progression or unacceptable toxicity. Patients undergo biopsy at baseline, 6 weeks, and 12 weeks and CT, PET/CT, or MRI throughout the trial.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Mayo Clinic

Lead Sponsor

Trials
3,427
Recruited
3,221,000+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+

Published Research Related to This Trial

Pembrolizumab, a PD-1 inhibitor, has demonstrated clinical effectiveness in treating various solid tumors, particularly in patients with PD-L1-positive non-small-cell lung cancer and unresectable/metastatic melanoma.
Early-phase trials and ongoing studies are focused on further confirming the clinical benefits of pembrolizumab in thoracic malignancies, highlighting its potential as a significant treatment option in cancer therapy.
Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions.Karim, S., Leighl, N.[2017]
In a phase II trial involving 159 patients with locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma, pembrolizumab showed significant antitumor activity, with an objective response rate of 50.0% in the locally advanced cohort and 35.2% in the recurrent/metastatic cohort.
The treatment demonstrated a manageable safety profile, with only 11.9% of patients experiencing grade 3-5 treatment-related adverse events, indicating that pembrolizumab is a promising and durable treatment option for cSCC.
Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial.Hughes, BGM., Munoz-Couselo, E., Mortier, L., et al.[2022]
Pembrolizumab is a monoclonal antibody that effectively blocks the PD-1 receptor on T cells, enhancing their ability to attack cancer cells, particularly in melanoma patients.
In a Phase I study involving 411 patients, pembrolizumab demonstrated high durable response rates with minimal toxicity, indicating its potential as a safe and effective treatment option for melanoma.
Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.Hersey, P., Gowrishankar, K.[2017]

Citations

Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions. [2017]
Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. [2022]
Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma. [2017]
Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience. [2022]
Pembrolizumab superior to ipilimumab in melanoma. [2017]
Pembrolizumab in the management of metastatic melanoma. [2020]
FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma. [2022]
FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma. [2021]
Real-world experience with pembrolizumab toxicities in advanced melanoma patients: a single-center experience in the UK. [2022]
Topical treatment of basal cell carcinoma with the immune response modifier imiquimod. [2018]
Digital follow-up by means of dermatoscopy and reflectance confocal microscopy of actinic keratosis treated with Imiquimod 3.75% cream. [2021]
Development and Optimization of Imiquimod-Loaded Nanostructured Lipid Carriers Using a Hybrid Design of Experiments Approach. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security